Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Filings
35 filings of ONESOURCE since January 2025.
board outcome 9, presentation 8, transcript 8, results 5, credit rating 4, scheme 1
| Filed | Type | Subject | |
|---|---|---|---|
| 03 Nov 2026 | transcript Capex, Guidance, Results | Onesource Specialty Pharma Limited has given an intimation of Transcript of Earnings call dated October 27, 2026AI summaryEarnings call transcript for Q2 FY27 (quarter ended September 30, 2026) of OneSource Specialty Pharma Limited, held October 27, 2026, filed under Regulation 30. Management (CEO Neeraj Sharma) said revenue rose 37% year-on-year and 15% sequentially to more than INR5 billion, EBITDA grew 53% year-on-year and 32% sequentially, and margin reached 32%, up more than 400 basis points quarter-on-quarter. Management said the second cartridge (DDC) line has been operational since September, with its third line now at the site for qualification, and commercialization may slip to the start of FY28. Management reaffirmed the FY28 outlook of $400 million revenue and $160 million EBITDA, and said the second half is expected to be stronger than the first. CFO Anurag Bhagania said geopolitical shipping disruption is delaying customer deliveries by 45 to 60 days, adding to working capital cycle times, which he described as temporary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | board outcome Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.AI summaryOneSource Specialty Pharma Limited filed its unaudited standalone financial results for the quarter and six months ended September 30, 2026, approved by the Board on October 27, 2026, with a limited review report from B S R & Co. LLP. Standalone revenue from operations for the quarter ended September 30, 2026 was Rs. 5,144.96 million, up from Rs. 3,751.87 million a year earlier. Standalone profit after tax for the quarter was Rs. 861.92 million, against Rs. 371.01 million in the corresponding quarter last year. Standalone revenue from operations for the six months ended September 30, 2026 was Rs. 9,609.67 million, and profit after tax was Rs. 1,374.17 million. Basic EPS for the quarter was Rs. 7.52 (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Sep 2026 | presentation | Onesource Specialty Pharma Limited has informed the Exchange about Investor PresentationAI summaryOneSource Specialty Pharma Limited intimated to BSE and NSE that it is holding an Analyst/Institutional Group Investor meeting on September 03, 2026 at its Manufacturing Facility (Unit II) in Doddaballapura, Bengaluru. The company has uploaded its latest Investor Presentation on its website. The filing does not include the presentation's financial figures or management commentary in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Aug 2026 | credit rating Rating | Onesource Specialty Pharma Limited has informed the Exchange about Credit RatingAI summaryOneSource Specialty Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on August 18, 2026 regarding a credit rating action by India Ratings & Research. India Ratings upgraded the long-term rating on INR 11,250.51 million of bank loan facilities to IND A/Positive from IND A-, and affirmed the short-term rating at IND A1. India Ratings assigned IND A/Positive/IND A1 to new bank loan facilities of INR 4,287.08 million. India Ratings cited the successful commercialisation of the drug-device combination platform and rising commercial GLP-1 supplies, with a Positive Outlook reflecting expected medium-term improvement in business profile and credit metrics. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2026 | transcript Capex, Dividend / buy-back, Guidance, Results | OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026AI summaryOneSource Specialty Pharma filed the transcript of its Q1 FY27 earnings call held July 25, 2026, for the quarter ended June 30, 2026. Management said revenue was INR4,490 million, up 37% year-on-year, and EBITDA was INR1,233 million, up 39% year-on-year and 34% sequentially. Management reiterated its FY28 outlook of $400 million organic revenue and EBITDA margins of 40%. Management said the second cartridge line is being set for commercialization this quarter, a second line is due within FY27, and a greenfield soft gelatin site is being planned. Management said the RFP funnel is almost 4x its level of just over a year ago and that it added six new logos and nine launches in the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jul 2026 | board outcome Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryAuditor's review report by Deloitte Haskins & Sells on the unaudited standalone and consolidated financial results of OneSource Specialty Pharma Limited for the quarter ended June 30, 2026, dated July 24, 2026. The auditor reports nothing has come to its attention that the results have not been prepared per Ind AS 34 and Regulation 33 of the LODR Regulations. For the consolidated results, the auditor did not review two subsidiaries (including a step-down subsidiary) with total revenues of Rs. 283.47 million, net loss after tax of Rs. 12.14 million and other comprehensive income of Rs. 12.44 million for the quarter; their reports were furnished by other auditors. Four further subsidiaries, with nil revenue and a total loss after tax of Rs. 1.79 million, were not reviewed by their auditors and are stated by management to be not material to the Group. The auditor's conclusions are not modified on these matters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated May 13, 2026.AI summaryTranscript of the Q4 and FY26 earnings conference call held May 13, 2026, filed under Regulation 30 for OneSource Specialty Pharma Limited. Management said Q4 FY26 revenue was INR4,282 million, up 47% sequentially, with Q4 EBITDA of INR919 million; FY26 revenue was INR14,216 million, down 2% year-on-year, and FY26 EBITDA declined about 35%. Management said adjusted PAT for Q4 was about INR390 million and for FY26 was INR739 million, with EPS of INR3.4 (Q4) and INR6.5 (FY26) on a fully diluted basis. Management reaffirmed its FY28 guidance of US$400 million organic revenue and around 40% EBITDA margin, and a 50%-plus ROCE expectation over the medium term. Management said the proposed Steriscience injectables and Brooks scheme has been deferred, with the company to re-look at it in about two years if needed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 May 2026 | presentation Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about Investor PresentationAI summaryOneSource Specialty Pharma filed its Q4FY26 and FY26 press release and investor presentation on May 13, 2026. Q4FY26 revenue was ₹4,282 million, up 47% QoQ; EBITDA was ₹919 million (21% margin) versus ₹173 million in Q3FY26; adjusted PAT was ₹390 million, with adjusted EPS of ₹3.4. FY26 revenue was ₹14,216 million (down 2% YoY) and FY26 EBITDA was ₹3,042 million (21% margin) versus ₹4,665 million in FY25. The company reaffirmed FY28 guidance of ~$400 million in organic revenue with ~40% EBITDA margin. CEO & MD Neeraj Sharma said management was well positioned to sustain growth momentum into FY27, citing India semaglutide launches and recent Canada semaglutide approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 May 2026 | board outcome Management change, Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryOneSource Specialty Pharma's board, meeting held May 13, 2026 (11:30 to 12:55 hrs IST), approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with the auditors' report enclosed. The auditors' report on the annual results carries an unmodified opinion, per the Regulation 33 declaration (Annexure A). The board approved appointing B S R & Co LLP, Chartered Accountants, as statutory auditors for five consecutive years, until the conclusion of the 24th AGM, in place of Deloitte Haskins & Sells, whose term ends at the ensuing AGM; the appointment is subject to shareholder approval. The filing does not state the financial figures, dividend or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Mar 2026 | credit rating Rating | Onesource Specialty Pharma Limited has informed the Exchange about reaffirmation and withdrawal of credit ratings by CareEdge Ratings ( CARE ).AI summaryOneSource Specialty Pharma Limited filed intimation under Regulation 30 of SEBI Listing Regulations on March 5, 2026 regarding credit ratings. CareEdge Ratings (CARE) reaffirmed bank facilities at CARE BBB+; Stable (long-term) and CARE A3+ (short-term), and the ratings were withdrawn at the company's request. CARE also withdrew the rating on the company's non-convertible debentures. The company states it maintains an IND A-; Positive rating from India Ratings & Research, reaffirmed in December 2025. The withdrawal is part of the company's periodic review and rationalisation of external credit ratings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2026 | transcript Capex, Guidance, Rating, Results | Onesource Specialty Pharma Limited has informed the Exchange about Transcript of the Earnings CallAI summaryOneSource Specialty Pharma filed the transcript of its Q3 FY26 earnings call (held January 24, 2026) for the quarter ended December 31, 2025. Management said Q3 revenue was about INR2,903 million, down 26% year-on-year, with EBITDA of INR173 million and adjusted PAT loss of INR472 million (adjusted diluted EPS negative 4.1), attributed to delayed Canadian semaglutide approvals for partners. Management reiterated FY28 guidance of $400 million revenue and $160 million EBITDA, and said it would not give FY26 or FY27 guidance until approvals are clearer. Management said it is spending over INR700 crores on capacity expansion and that interest cost is now 200 bps lower, with an effective rate below 9%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2026 | presentation Acquisition, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about Investor PresentationAI summaryOneSource Specialty Pharma filed its Q3FY26 press release and investor presentation (quarter ended December 31, 2025), with the consolidated results. Q3FY26 revenue was ₹2,903 million, down 26% YoY; EBITDA was ₹173 million (6% margin), down 88% YoY; Adjusted PAT was (₹472) million with Adjusted EPS of (₹4.1). Management (CEO & MD Neeraj Sharma) said the quarter was subdued due to delays in customer approvals in Canada for semaglutide, which prolonged the transition from MSA to CSA phase, while order book continues to trend upward. The company reaffirmed FY28 guidance of ₹400 million organic revenue (₹500 million including the proposed acquisition) with a ~40% EBITDA margin outlook, subject to shareholder approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2026 | board outcome Acquisition, Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, approved by the Board on January 23, 2026 (meeting 16:55 to 19:00 hrs IST), with a limited review report from Deloitte Haskins & Sells. Standalone revenue from operations for the quarter ended December 31, 2025 was Rs. 2,902.20 million, against Rs. 3,751.87 million in the previous quarter (September 30, 2025) and Rs. 3,367.49 million a year earlier. Standalone loss after tax for the quarter ended December 31, 2025 was Rs. 621.85 million, against a profit of Rs. 371.01 million in the previous quarter; the quarter includes exceptional items of Rs. 70.90 million. For the nine months ended December 31, 2025, standalone loss after tax was Rs. 2.69 million, against a loss of Rs. 1,548.77 million a year earlier. The notes state that a composite scheme of arrangement and amalgamation, approved by the Board on September 26, 2025, is pending regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jan 2026 | board outcome Acquisition, Results | Onesource Specialty Pharma Limited has informed the Exchange regarding Board meeting held on January 23, 2026 for approving the unaudited financial results for the quarter ended December 31,2025AI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, approved by the Board on January 23, 2026, with a limited review report from Deloitte Haskins & Sells. Standalone revenue from operations was Rs. 2,902.20 million for the quarter ended December 31, 2025, against Rs. 3,751.87 million for the quarter ended September 30, 2025 and Rs. 3,367.49 million for the quarter ended December 31, 2024. Standalone result was a loss after tax of Rs. 621.85 million for the quarter ended December 31, 2025, against a profit of Rs. 371.01 million in the previous quarter; exceptional items were Rs. 70.90 million in the quarter. For the nine months ended December 31, 2025, standalone revenue from operations was Rs. 9,864.19 million and loss after tax was Rs. 2.69 million. The company is in the process of obtaining regulatory approvals for a composite scheme of arrangement and amalgamation approved by its Board on September 26, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Nov 2025 | transcript Acquisition, Capex, Guidance, Legal, Results | Onesource Specialty Pharma Limited has informed the Exchange about TranscriptAI summaryOneSource Specialty Pharma filed the transcript of its Q2 FY26 earnings conference call held on November 12, 2025, for the quarter and half year ended September 30, 2025. Management (Neeraj Sharma, CEO and MD) said Q2 revenue was INR3,758 million, up 12% year-on-year, with EBITDA of INR1,065 million (up 37%) at a 28% margin. For H1 FY26, management reported revenue of INR7,030 million (up 12%) and EBITDA of INR1,950 million at a 28% margin; adjusted fully diluted EPS for the quarter was INR3.9. Management reiterated FY28 guidance of INR500 million (subject to shareholder approvals for inorganic businesses) and said it would give more specific next-year guidance around end of March, as Canadian semaglutide launch timing is uncertain. Net debt stood at INR9,033 million, up INR4,326 million from March 2025, with working capital elevated due to inventory build for upcoming drug-device combination launches. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | presentation Acquisition, Capex, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about Investor PresentationAI summaryOneSource Specialty Pharma filed its Q2FY26 earnings investor presentation dated November 12, 2025, after a board meeting held November 11, 2025 (16:10 to 16:35 hrs IST). Q2FY26 revenue was ₹3,758m ($43.1m), up 12% YoY; EBITDA was ₹1,065m ($12.2m), up 37% YoY, with a 28% margin (about 506 bps YoY improvement). Reported PAT was ₹105m ($1.2m) versus a loss of ₹421m in Q2FY25; Adjusted PAT was ₹449m ($5.2m), with Adjusted EPS of ₹3.9. Management said it is raising its FY28 revenue outlook to $500m+ following the recently proposed acquisition of a multi-dose fill-finish site in Europe and an integrated carbapenem facility in India. As of September 30, 2025, net debt for the incoming business was $11.5m (including working capital limits), trending towards $7–8 million as guided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Nov 2025 | board outcome Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryOneSource Specialty Pharma Limited filed the outcome of its board meeting held November 11, 2025, approving unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2025, with a Limited Review Report from Deloitte Haskins & Sells. Consolidated revenue from operations for the quarter ended September 30, 2025 was Rs. 3,757.63 million, against Rs. 3,272.70 million in the quarter ended June 30, 2025 and Rs. 3,340.48 million in the quarter ended September 30, 2024. Consolidated profit after tax for the quarter ended September 30, 2025 was Rs. 104.85 million, against a loss of Rs. 420.77 million in the corresponding quarter last year. Consolidated revenue for the half year ended September 30, 2025 was Rs. 7,030.33 million, against Rs. 6,263.37 million a year earlier; half-year profit after tax was Rs. 102.99 million, against a loss of Rs. 476.24 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Sep 2025 | presentation Acquisition, Dividend / buy-back, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about Presentation on Merger and Other restructuringAI summaryOneSource Specialty Pharma filed an investor presentation on the Board-approved strategic transaction to acquire the European CDMO business of Steriscience and the anti-infective business of Brooks Steriscience, via a scheme of merger. The transaction values OneSource at $2.7 billion, an 18.6% premium to the closing price of September 26, 2025; the combined company is expected to have about 140.64 million shares post closing, with total dilution of 18.5% for OneSource shareholders. Upgraded FY28 outlook: revenue of $500+ million and EBITDA margin of about 40% (organic plus transaction growth), versus the prior organic-only FY28 outlook of $400 million revenue and about 40% EBITDA margin. The Steriscience and Brooks Steriscience assets are forecast at FY27 revenue of $73 million and $34 million, and EBITDA of $29 million and $10 million, respectively. The scheme is expected to take up to 15 months to close, with an appointed date of 01 April 2026 for the Indian entity mergers. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Sep 2025 | scheme Acquisition, Legal | Onesource Specialty Pharma Limited has informed the Exchange about Amalgamation/MergerAI summaryOneSource Specialty Pharma's board approved a composite scheme of arrangement and amalgamation (merger by absorption) with Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte Limited (Singapore) and Strides Pharma Services Private Limited, with OneSource as the ultimate transferee company. The board meeting ran from 20:00 to 20:36 hrs IST on September 26, 2025, and the scheme was reviewed and recommended by the Audit Committee and the Committee of Independent Directors. The scheme is subject to approval from shareholders, creditors, BSE, NSE, SEBI, the National Company Law Tribunal, the Singapore Court and other authorities. Turnover and net worth of the entities were disclosed: OneSource turnover INR 12,995.89 million and net worth INR 59,108.37 million (standalone, FY2024-25). The scheme is treated as a related party transaction under Regulation 23 of the SEBI Listing Regulations because the companies share common promoters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | transcript Acquisition, Capex, Guidance, Rating, Results | Onesource Specialty Pharma Limited has informed the Exchange about Transcript of the Earnings call held on August 05, 2025AI summaryTranscript of OneSource Specialty Pharma's Q1 FY26 earnings call (held August 5, 2025), filed under Regulation 30 for the quarter ended June 30, 2025. Management said Q1 revenue was INR 3,273 million, up 12% year-over-year, with EBITDA up 37% to INR 885 million and margin up about 500 bps to 27%. Adjusted PAT was about INR 371 million and adjusted fully diluted EPS was INR 3.2; management said a credit rating upgrade was received, taking the company into the "A" category. Management announced a potential transaction to evaluate acquiring two CDMO assets (a Polish facility and the Baroda JV with Brooks) with about $65 million FY26 revenue and $36-40 million EBITDA; the Board has formed an independent committee of three directors to evaluate it, and management said it is early stage and subject to approvals. Management reiterated a target of $400 million organic revenue by FY28 and a debt-to-EBITDA ratio below 1.5x, with the capex plan of $100 million being accelerated. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | board outcome Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma) filed the outcome of its board meeting held August 04, 2025 (17:30 to 18:50 hrs IST), approving unaudited consolidated and standalone financial results for the quarter ended June 30, 2025, with Deloitte Haskins & Sells' limited review report. Consolidated revenue from operations for Q1 FY26 (quarter ended June 30, 2025) was Rs. 3,272.70 million, against Rs. 4,259.53 million in the March 31, 2025 quarter and Rs. 2,922.89 million in the June 30, 2024 quarter. Consolidated loss after tax from continuing operations for the June 30, 2025 quarter was Rs. 1.86 million, compared with a loss of Rs. 55.47 million in the June 30, 2024 quarter. Consolidated total comprehensive income for the June 30, 2025 quarter was Rs. 28.27 million; basic EPS was Rs. (0.02), against Rs. (0.51) a year earlier. Finance costs were Rs. 274.78 million and exceptional loss was Rs. 28.70 million for the June 30, 2025 quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Jul 2025 | results Acquisition, Legal, Results | The Exchange had sought clarification from Onesource Specialty Pharma Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of aboveAI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma) filed an intimation dated May 5, 2025 that its board, at a meeting on that day, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with the auditors' report enclosed. The board also approved appointment of M/s. D V & Associates as Secretarial Auditor for a term of 5 years. The board gave in-principle approval to consolidate the Singapore business operations of its wholly owned subsidiary Stelis Pte Ltd and/or its step-down subsidiary Strides Softgel Pte Ltd into another wholly owned subsidiary, Onesource Specialty Pte Ltd. The filing states that the company fully redeemed its 20,000 secured, rated, redeemable NCDs on November 28, 2024, so certain debt-related intimations are not required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jun 2025 | results | The Exchange has sought clarification from Onesource Specialty Pharma Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above | |
| 04 Jun 2025 | credit rating Rating | Onesource Specialty Pharma Limited has informed the Exchange about Credit RatingAI summaryOneSource Specialty Pharma Limited filed an intimation under Regulation 30 and Regulation 51 of the SEBI Listing Regulations, dated June 04, 2025, informing exchanges of a credit rating. India Ratings & Research assigned 'IND A-' with Positive Outlook to the company's bank facilities, with the press release dated June 03, 2025 attached. Rated facilities include a term loan of INR2,015.09 million, fund-based working capital limits of INR5,200 million (IND A-/Positive/IND A1) and non-fund-based working capital limits of INR200 million (IND A1). The rationale cites expected healthy revenue/EBITDA from softgel and injectable businesses, GLP-1 commercialisation, and FY25 net leverage improvement, with rating sensitivities including net leverage (net debt/EBITDA) above 1.5x as negative. The agency noted INR11,648 million of contingent liabilities linked to the terminated Sputnik Light Vaccines supply contract, which it has not factored into cash outflow estimates. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2025 | transcript Capex, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about TranscriptAI summaryTranscript of OneSource Specialty Pharma's Q4 and full-year FY25 earnings call held May 06, 2025, with management Arun Kumar (Founder and Non-Executive Chairperson), Neeraj Sharma (CEO and MD) and Anurag Bhagania (CFO). Management reported Q4 revenue of INR4,260 million (up 22%), Q4 operating EBITDA of INR1,825 million (up 79%) and Q4 PAT of INR992 million versus a loss in the prior year; full-year FY25 revenue was INR14,449 million (up 30%), EBITDA INR4,665 million and adjusted PAT INR936 million. Management said FY26 will be a transition year with lumpy, H2-weighted DDC commercial supplies dependent on approvals, and reaffirmed the FY28 outlook of $400 million revenue and 38-40% EBITDA margin, with a FY25-FY28 revenue CAGR of 30%. Management said it plans about $100 million of capacity and capability investment over the next couple of years, aims to be net debt free in 2-3 years, and that net debt was INR4,707 million at the end of the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 May 2025 | presentation | Onesource Specialty Pharma Limited has informed the Exchange about Investor PresentationAI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited) filed an intimation under SEBI LODR Regulation 30 of the audio/video recording of its Q4 FY25 earnings call held on May 06, 2025. The recording is available on the company website. The filing does not state any financial results, guidance or management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 May 2025 | board outcome Acquisition, Legal, Management change, Results | Onesource Specialty Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2025.AI summaryBoard outcome filed on May 5, 2025 following a meeting held that day (15:45 to 19:15 IST) by OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited). The board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with the auditors' report enclosed. The board appointed M/s. D V & Associates as Secretarial Auditor for a term of 5 years. The board gave in-principle approval to consolidate the Singapore business operations of Stelis Pte Ltd and/or Strides Softgel Pte Ltd into Onesource Specialty Pte Ltd, a wholly owned subsidiary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Apr 2025 | presentation Results | Onesource Specialty Pharma Limited has informed the Exchange about Schedule of meet and PresentationAI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma) intimated that its Board meeting on Monday, May 05, 2025 will consider audited financial results for the quarter and year ended March 31, 2025. The trading window for the Q4 earnings release remains closed until 48 hours after dissemination of the audited results. An investor and analyst conference call on Q4 and FY25 results is scheduled for Tuesday, May 06, 2025 at 09:00 hrs IST. Speakers on the call are Arun Kumar (Founder and Non-Executive Chairperson), Neeraj Sharma (CEO and MD) and Anurag Bhagania (CFO). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Feb 2025 | credit rating Dividend / buy-back, Rating | Onesource Specialty Pharma Limited has informed the Exchange about Credit RatingAI summaryOneSource Specialty Pharma filed a Regulation 30/51 intimation to BSE and NSE enclosing a CARE Ratings press release dated February 20, 2025. CARE upgraded long-term bank facilities to CARE BBB+; Stable from CARE BB+, with the amount enhanced from ₹120.10 crore to ₹215 crore, and removed them from Rating Watch with Developing Implications. CARE assigned CARE BBB+; Stable to ₹100 crore non-convertible debentures and CARE BBB+; Stable; CARE A3+ to ₹540 crore long-term/short-term bank facilities. Existing CE-backed ratings of CARE A(CE); Stable on bank facilities and NCDs were reaffirmed and withdrawn after Strides Pharma's corporate guarantee was released; ₹200 crore listed NCDs were withdrawn after repayment. CARE's outlook is Stable, and it noted Q3FY25 PBILDT margin of about 36% and 9MFY25 TOI of ₹1,032 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2025 | results Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.AI summaryAuditor Deloitte Haskins & Sells issued a review report (dated 23 October 2024) on the unaudited standalone and consolidated financial results of OneSource Speciality Pharma Limited (formerly Stelis Biopharma Limited) for the quarter and six months ended 30 September 2024. The review found nothing to indicate the statements contain a material misstatement or fail to meet SEBI Regulations 52 and 54. The consolidated statement covers the parent and three subsidiaries: Biolexis Private Limited, Biolexis Pte. Ltd. and Stelis Pte. Limited. One subsidiary, reviewed by another auditor, shows total revenues of Rs. 240.36 million and total loss after tax of Rs. (59.26) million for the quarter and six months ended 30 September 2024. The comparative quarter and six-month figures for 30 September 2023 were prepared by management and were neither audited nor reviewed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Feb 2025 | transcript Capex, Guidance, Results | Onesource Specialty Pharma Limited has informed the Exchange about TranscriptAI summaryOneSource Specialty Pharma filed the transcript of its Q3 and 9-month FY25 earnings conference call held on January 29, 2025. Management reported Q3 revenue of INR393 crores and EBITDA of INR143 crores, with a 36% EBITDA margin; 9-month revenue was about INR1,000 crores and 9-month EBITDA about INR284 crores. Management reaffirmed medium-term guidance of 25% to 30% CAGR growth, reaching a INR400 crore revenue run-rate in 3 to 4 years with a 40% EBITDA margin. Management said it plans about $100 million of capex over 2 to 4 years, with about half funded from the INR801 crore fundraise and the rest from internal accruals and customer participation. Management said net debt was INR581 crores at quarter end and it aims to be debt free before end of FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jan 2025 | results Acquisition, Legal, Results | Intimation of integrated financial results for the quarter ended December 31,2024. The same was tried to be uploaded on 29.01.2025, however we were unable to upload the same due to technical issues. Attaching the screenshot of the error alsAI summaryOneSource Specialty Pharma Limited (formerly Stelis Biopharma) filed its unaudited standalone financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 29, 2025, with an unmodified limited review conclusion from Deloitte Haskins & Sells. Q3 FY25 revenue from operations was Rs. 3,367.49 million, against Rs. 2,454.00 million in the September 30, 2024 quarter and Rs. 562.05 million in the December 31, 2023 quarter. Q3 FY25 loss after tax was Rs. 730.23 million, with basic loss per share of Rs. (6.69); nine-month loss after tax was Rs. 1,548.77 million. The results reflect the merger of the CDMO and Soft Gelatin businesses of Strides Pharma Science and the CDMO business of Steriscience under a scheme effective November 27, 2024, with appointed date April 1, 2024; the company recorded goodwill of Rs. 19,761.42 million. Exceptional items for the quarter were a net loss of Rs. 1,005.23 million, mainly business combination, listing and post-merger integration expenses. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2025 | presentation Results | Earnings Presentation for the quarter ended December 31,2024AI summaryOneSource Specialty Pharma filed its Q3FY25 (quarter ended December 31, 2024) press release and earnings presentation on January 29, 2025. Q3FY25 revenues were ₹3,926 million, up 18% QoQ; EBITDA was ₹1,432 million, up 85% QoQ, with an EBITDA margin of 36.5%. Normalised PAT was ₹898 million, with normalised EPS of ₹7.8 per share; reported PAT was impacted by one-time setup and transaction costs (exceptional items of ₹1,005 million). Management (CEO Neeraj Sharma) said the company is off to a promising start as an independent platform and is on the path to continued growth and profitability while achieving targeted FY25 outcomes. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2025 | results Results | Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryOnesource Specialty Pharma Limited (formerly Stelis Biopharma) filed unaudited consolidated financial results for the quarter and nine months ended December 31, 2024, with auditor Deloitte Haskins & Sells issuing a limited review report dated January 29, 2025. Consolidated revenue from operations was Rs. 3,925.63 million for the quarter ended December 31, 2024, compared with Rs. 3,340.48 million for the quarter ended September 30, 2024 and Rs. 562.05 million for the quarter ended December 31, 2023. Consolidated loss after tax from continuing operations was Rs. 688.49 million for the quarter ended December 31, 2024, and loss for the nine months ended December 31, 2024 was Rs. 1,164.73 million. Exceptional items for the quarter ended December 31, 2024 were Rs. (1,005.23) million. Basic loss per share (Rs. 1/- face value, not annualised) for the quarter ended December 31, 2024 was Rs. (6.31). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2025 | board outcome Results | Onesource Specialty Pharma Limited has informed the Exchange regarding Board meeting held on January 29, 2025 for approval of unaudited financial results (Standalone and Consolidated) for the quarter ended December 31,2024.AI summaryBoard outcome filing of OneSource Specialty Pharma Limited (formerly Stelis Biopharma) with Deloitte Haskins & Sells review reports dated January 29, 2025, on unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. Consolidated revenue from operations was Rs. 3,925.63 million for the quarter ended December 31, 2024 (Rs. 3,340.48 million for the quarter ended September 30, 2024) and Rs. 10,189.00 million for the nine months ended December 31, 2024. Consolidated loss after tax from continuing operations was Rs. 688.49 million for the quarter ended December 31, 2024 and Rs. 1,164.73 million for the nine months ended December 31, 2024. Consolidated basic loss per share was Rs. (6.31) for the quarter ended December 31, 2024 and Rs. (10.68) for the nine months ended December 31, 2024 (not annualised). Paid-up equity share capital rose to Rs. 114.43 million at December 31, 2024 from Rs. 41.55 million at September 30, 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.